Production of recombinant coagulation factors: Are humans the best host cells?

Bioengineered

Virgínia Picanço-Castro¹  Dimas Tadeu Covas²  Kamilla Swiech³ 

[1] Center for Cell-based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto-SP, Brazi;Center for Cell-based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto-SP, Brazi;Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazi;Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, São Paulo, Brazi;Center for Cell-based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto-SP, Brazi;

关键词: factor VIII;    factor IX;    hemophilia;    human cell lines;    immunogenicity;    recombinant coagulation factors;    recombinant protein production;   

DOI  :  10.1080/21655979.2017.1279767

来源: Taylor & Francis

【 摘 要 】

The main treatment option for Hemophilia A/B patients involves the administration of recombinant coagulation factors on-demand or in a prophylactic approach. Despite the safety and efficacy of this replacement therapy, the development of antibodies against the coagulation factor infused, which neutralize the procoagulant activity, is a severe complication. The production of recombinant coagulation factors in human cell lines is an efficient approach to avoid such complication. Human cell lines can produce recombinant proteins with post translation modifications more similar to their natural counterpart, reducing potential immunogenic reactions. This review provides a brief overview of the most important characteristics of recombinant FVIII and FIX products available on the market and the improvements that have recently been achieved by the production using human cell lines.

【 授权许可】

Unknown